U.S. Department of Health & Human Services Divider Arrow National Institutes of Health Divider Arrow NCATS

Details

Stereochemistry ABSOLUTE
Molecular Formula C20H25N3O2
Molecular Weight 339.4314
Optical Activity UNSPECIFIED
Defined Stereocenters 3 / 3
E/Z Centers 0
Charge 0

SHOW SMILES / InChI
Structure of METHYLERGONOVINE

SMILES

[H][C@@]12CC3=CNC4=C3C(=CC=C4)C1=C[C@H](CN2C)C(=O)N[C@@H](CC)CO

InChI

InChIKey=UNBRKDKAWYKMIV-QWQRMKEZSA-N
InChI=1S/C20H25N3O2/c1-3-14(11-24)22-20(25)13-7-16-15-5-4-6-17-19(15)12(9-21-17)8-18(16)23(2)10-13/h4-7,9,13-14,18,21,24H,3,8,10-11H2,1-2H3,(H,22,25)/t13-,14+,18-/m1/s1

HIDE SMILES / InChI

Molecular Formula C20H25N3O2
Molecular Weight 339.4314
Charge 0
Count
Stereochemistry ABSOLUTE
Additional Stereochemistry No
Defined Stereocenters 3 / 3
E/Z Centers 0
Optical Activity UNSPECIFIED

Description
Curator's Comment: Description was created based on several sources, including http://www.accessdata.fda.gov/drugsatfda_docs/nda/2012/006035Orig1S078.pdf

Methylergometrine (other names include methylergonovine, methylergobasin, methergine, and D-lysergic acid 1-butanolamide) is a synthetic analogue of ergonovine, a psychedelic alkaloid found in ergot, and many species of morning glory. In general, the effects of all the ergot alkaloids appear to results from their actions as partial agonists or antagonists at adrenergic, dopaminergic, and tryptaminergic receptors. The spectrum of effects depends on the agent, dosage, species, tissue, and experimental or physiological conditions. All of the alkaloids of ergot significantly increase the motor activity of the uterus. After small doses contractions are increased in force or frequency, or both, but are followed by a normal degree of relaxation. As the dose is increased, contractions become more forceful and prolonged, resting tonus is markedly increased, and sustained contracture can result. Methylergometrine acts directly on the smooth muscle of the uterus and increases the tone, rate, and amplitude of rhythmic contractions through binding and the resultant antagonism of the dopamine D1 receptor. Thus, it induces a rapid and sustained tetanic uterotonic effect which shortens the third stage of labor and reduces blood loss. Methylergometrine is used for the prevention and control of excessive bleeding following vaginal childbirth.

Approval Year

TargetsConditions

Conditions

ConditionModalityTargetsHighest PhaseProduct
Primary
METHERGINE

Approved Use

Following delivery of the placenta, for routine management of uterine atony, hemorrhage and subinvolution of the uterus. For control of uterine hemorrhage in the second stage of labor following delivery of the anterior shoulder.

Launch Date

1946
Cmax

Cmax

ValueDoseCo-administeredAnalytePopulation
5918 pg/mL
0.2 mg single, intramuscular
dose: 0.2 mg
route of administration: Intramuscular
experiment type: SINGLE
co-administered:
METHYLERGONOVINE plasma
Homo sapiens
population: HEALTHY
age: ADULT
sex: FEMALE
food status: FASTED
AUC

AUC

ValueDoseCo-administeredAnalytePopulation
13889 pg × h/mL
0.2 mg single, intramuscular
dose: 0.2 mg
route of administration: Intramuscular
experiment type: SINGLE
co-administered:
METHYLERGONOVINE plasma
Homo sapiens
population: HEALTHY
age: ADULT
sex: FEMALE
food status: FASTED
T1/2

T1/2

ValueDoseCo-administeredAnalytePopulation
3.39 h
0.2 mg single, intramuscular
dose: 0.2 mg
route of administration: Intramuscular
experiment type: SINGLE
co-administered:
METHYLERGONOVINE plasma
Homo sapiens
population: HEALTHY
age: ADULT
sex: FEMALE
food status: FASTED
Doses

Doses

DosePopulationAdverse events​
0.2 mg single, intramuscular
Overdose
Dose: 0.2 mg
Route: intramuscular
Route: single
Dose: 0.2 mg
Sources:
healthy, newborns
Health Status: healthy
Age Group: newborns
Sources:
Other AEs: Respiratory depression, Hypothermia...
Other AEs:
Respiratory depression
Hypothermia
Hypertonicity
Jerky movement NOS
Convulsions
Sources:
0.8 mg multiple, oral
Highest studied dose
healthy
Health Status: healthy
Condition: uterine atony and hemorrhage prophylaxis
Sex: F
Sources:
0.2 mg single, intravenous
Recommended
Dose: 0.2 mg
Route: intravenous
Route: single
Dose: 0.2 mg
Sources:
unhealthy
Health Status: unhealthy
Condition: uterine hemorrhage
Sources:
Other AEs: Hypertension, Cerebrovascular accident...
Other AEs:
Hypertension
Cerebrovascular accident
Sources:
AEs

AEs

AESignificanceDosePopulation
Convulsions
0.2 mg single, intramuscular
Overdose
Dose: 0.2 mg
Route: intramuscular
Route: single
Dose: 0.2 mg
Sources:
healthy, newborns
Health Status: healthy
Age Group: newborns
Sources:
Hypertonicity
0.2 mg single, intramuscular
Overdose
Dose: 0.2 mg
Route: intramuscular
Route: single
Dose: 0.2 mg
Sources:
healthy, newborns
Health Status: healthy
Age Group: newborns
Sources:
Hypothermia
0.2 mg single, intramuscular
Overdose
Dose: 0.2 mg
Route: intramuscular
Route: single
Dose: 0.2 mg
Sources:
healthy, newborns
Health Status: healthy
Age Group: newborns
Sources:
Jerky movement NOS
0.2 mg single, intramuscular
Overdose
Dose: 0.2 mg
Route: intramuscular
Route: single
Dose: 0.2 mg
Sources:
healthy, newborns
Health Status: healthy
Age Group: newborns
Sources:
Respiratory depression
0.2 mg single, intramuscular
Overdose
Dose: 0.2 mg
Route: intramuscular
Route: single
Dose: 0.2 mg
Sources:
healthy, newborns
Health Status: healthy
Age Group: newborns
Sources:
Cerebrovascular accident
0.2 mg single, intravenous
Recommended
Dose: 0.2 mg
Route: intravenous
Route: single
Dose: 0.2 mg
Sources:
unhealthy
Health Status: unhealthy
Condition: uterine hemorrhage
Sources:
Hypertension
0.2 mg single, intravenous
Recommended
Dose: 0.2 mg
Route: intravenous
Route: single
Dose: 0.2 mg
Sources:
unhealthy
Health Status: unhealthy
Condition: uterine hemorrhage
Sources:
Overview

Overview

CYP3A4CYP2C9CYP2D6hERG

OverviewOther

Other InhibitorOther SubstrateOther Inducer
Drug as victim

Drug as victim

TargetModalityActivityMetaboliteClinical evidence
yes
PubMed

PubMed

TitleDatePubMed
Coronary artery spasm triggered by oral administration of methylergometrine.
1991 Aug 3
Delayed vasospasm in late postpartum cerebral angiopathy after withdrawal of methylergometrine.
2002
Pregnancy with acute intermittent porphyria: a case report and review of literature.
2002 Jun
Postpartum hemorrhage: new management options.
2002 Jun
The human G protein beta 3 subunit GNB3 825T polymorphism.
2002 May
Mouse model of Prinzmetal angina by disruption of the inward rectifier Kir6.1.
2002 May
Prevention and treatment of postpartum endometritis.
2003 Aug
Pharmacological characterization of 5-HT(1B) receptor-mediated inhibition of local excitatory synaptic transmission in the CA1 region of rat hippocampus.
2003 Jan
Effects of methylergometrine and oxytocin on thoracic epidural pressure during cesarean section.
2003 Jun
Postpartum second degree heart block induced by Methergine.
2003 May
B-Lynch Brace Suturing in primary post-partum hemorrhage during cesarean section.
2003 Oct
Myocardial ischemia induced by intramyometrial injection of methylergonovine maleate.
2004 Apr
Skeletonization does not influence internal thoracic artery innervation.
2004 Apr
Misoprostol versus methylergometrine: pharmacokinetics in human milk.
2004 Dec
[Revelation of a coronary spasm using the Méthergin test].
2004 Jan 24
Acute postpuerperal necrotizing endomyometritis.
2004 Jul
[Tako-tsubo: a rare form of transient left ventricular dysfunction].
2005 Apr
Accidental child poisoning with methylergometrine intended for the mother.
2005 Feb
[Acute myocardial infarction due to coronary artery spasm after caesarean section].
2005 Jan
Methylergonovine maleate (methergine) relieves postdural puncture headache in obstetric patients.
2005 Jan
Oral misoprostol versus injectable methylergometrine in management of the third stage of labor.
2005 Nov
Myocardial infarction and mortality caused by methylergonovine.
2005 Oct
The MFMU Cesarean Registry: uterine atony after primary cesarean delivery.
2005 Sep
The role of serendipity in drug discovery.
2006
[Intraoperative anaphylactic shock induced by methylergometrine and oxytocin].
2006 Apr
[B lynch suture for post partum heamorrhage due to uterine atony].
2006 Feb
Effect of estradiol 17beta upon coronary artery vasoconstrictor response to methylergometrine maleate in female menopausal patients.
2006 Feb 15
[Myocardial bridging and coronary spasm on effort].
2006 Jan
[Effects of methylergometrine and oxytocin on blood loss and uterine contraction during cesarean section].
2006 May
Oral misoprostol for the prevention of primary post-partum hemorrhage during third stage of labor.
2007 Dec
[Two cases of congenital airway obstruction managed with ex utero intrapartum treatment procedures: anesthetic implications].
2007 Jan
Early lactation performance in primiparous and multiparous women in relation to different maternity home practices. A randomised trial in St. Petersburg.
2007 May 8
[Case report of a successful pregnancy following thrombolysis for acute myocardial infarction].
2007 Nov
A study of prophylactic use of 15-methyl prostalglandin F2alpha in the active management of third stage of labour.
2007 Sep
Complete uterine inversion during caesarean section: A case report.
2008 Aug 27
[Case of peripartum cardiomyopathy developed after an emergency cesarean section--a case report].
2008 Feb
Bromocriptine, a dopamine D(2) receptor agonist with the structure of the amino acid ergot alkaloids, induces neurite outgrowth in PC12 cells.
2008 Nov 19
Low-dose sublingual misoprostol versus methylergometrine for active management of the third stage of labor.
2008 Oct
Postpartum severe sinus bradycardia following methylergonovine administration.
2008 Sep-Oct
Appetite suppressants, cardiac valve disease and combination pharmacotherapy.
2009 Jul-Aug
Coronary artery spasm and dobutamine stress echocardiography.
2009 Jun
Acute myocardial infarction following oral methyl-ergometrine intake.
2009 Mar
Management of cardiac arrest caused by coronary artery spasm: epinephrine/adrenaline versus nitrates.
2009 May-Jun
Efavirenz: a decade of clinical experience in the treatment of HIV.
2009 Nov
Emergent management of postpartum hemorrhage for the general and acute care surgeon.
2009 Nov 25
Efficacy and tolerability of intravenous methylergonovine in migraine female patients attending the emergency department: a pilot open-label study.
2009 Nov 8
Association of ornithine transcarbamylase gene polymorphisms with hypertension and coronary artery vasomotion.
2009 Sep
Severe vaginal bleeding secondary to cesarean scar dehiscence following incomplete abortion management.
2010 Feb
Care during the third stage of labour: obstetricians views and practice in an Albanian maternity hospital.
2010 Jan 26
Application of uterotonics on the basis of regular ultrasonic evaluation of the uterus prevents unnecessary surgical intervention in the postpartum period.
2010 Sep
Patents

Sample Use Guides

Intramuscularly 1 mL, 0.2 mg, after delivery of the anterior shoulder, after delivery of the placenta, or during the puerperium. May be repeated as required, at intervals of 2-4 hours. Intravenously 1 mL, 0.2 mg, administered slowly over a period of no less than 60 seconds Orally One tablet, 0.2 mg, 3 or 4 times daily in the puerperium for a maximum of 1 week.
Route of Administration: Other
In Vitro Use Guide
Unknown
Substance Class Chemical
Created
by admin
on Sat Dec 16 17:45:11 GMT 2023
Edited
by admin
on Sat Dec 16 17:45:11 GMT 2023
Record UNII
W53L6FE61V
Record Status Validated (UNII)
Record Version
  • Download
Name Type Language
METHYLERGONOVINE
MI   VANDF  
Common Name English
METHYLERGOMETRINE [HSDB]
Common Name English
(8.BETA.)-N-((1S)-1-(HYDROXYMETHYL)PROPYL)-6-METHYL-9,10-DIDEHYDROERGOLINE-8-CARBOXAMIDE
Systematic Name English
ERGOTYL
Brand Name English
(8β)-N-[(2S)-1-hydroxybutan-2-yl]-6-methyl-9,10-didehydroergoline-8-carboxamide
Systematic Name English
methylergometrine [INN]
Common Name English
ERGOMETRINE MALEATE IMPURITY D [EP IMPURITY]
Common Name English
METHYLERGONOVINE [VANDF]
Common Name English
Methylergometrine [WHO-DD]
Common Name English
METHYLERGONOVINE [MI]
Common Name English
METHYLERGOMETRINE
HSDB   INN   WHO-DD  
INN  
Official Name English
Classification Tree Code System Code
NCI_THESAURUS C47795
Created by admin on Sat Dec 16 17:45:12 GMT 2023 , Edited by admin on Sat Dec 16 17:45:12 GMT 2023
NDF-RT N0000007618
Created by admin on Sat Dec 16 17:45:12 GMT 2023 , Edited by admin on Sat Dec 16 17:45:12 GMT 2023
NDF-RT N0000175827
Created by admin on Sat Dec 16 17:45:12 GMT 2023 , Edited by admin on Sat Dec 16 17:45:12 GMT 2023
WHO-VATC QG02AB01
Created by admin on Sat Dec 16 17:45:12 GMT 2023 , Edited by admin on Sat Dec 16 17:45:12 GMT 2023
WHO-ATC G02AC01
Created by admin on Sat Dec 16 17:45:12 GMT 2023 , Edited by admin on Sat Dec 16 17:45:12 GMT 2023
WHO-VATC QG02AC01
Created by admin on Sat Dec 16 17:45:12 GMT 2023 , Edited by admin on Sat Dec 16 17:45:12 GMT 2023
WHO-ATC G02AB01
Created by admin on Sat Dec 16 17:45:12 GMT 2023 , Edited by admin on Sat Dec 16 17:45:12 GMT 2023
NDF-RT N0000007618
Created by admin on Sat Dec 16 17:45:12 GMT 2023 , Edited by admin on Sat Dec 16 17:45:12 GMT 2023
Code System Code Type Description
EPA CompTox
DTXSID00904978
Created by admin on Sat Dec 16 17:45:12 GMT 2023 , Edited by admin on Sat Dec 16 17:45:12 GMT 2023
PRIMARY
MERCK INDEX
m7412
Created by admin on Sat Dec 16 17:45:12 GMT 2023 , Edited by admin on Sat Dec 16 17:45:12 GMT 2023
PRIMARY Merck Index
NCI_THESAURUS
C74105
Created by admin on Sat Dec 16 17:45:12 GMT 2023 , Edited by admin on Sat Dec 16 17:45:12 GMT 2023
PRIMARY
DAILYMED
W53L6FE61V
Created by admin on Sat Dec 16 17:45:12 GMT 2023 , Edited by admin on Sat Dec 16 17:45:12 GMT 2023
PRIMARY
EVMPD
SUB08868MIG
Created by admin on Sat Dec 16 17:45:12 GMT 2023 , Edited by admin on Sat Dec 16 17:45:12 GMT 2023
PRIMARY
INN
2900
Created by admin on Sat Dec 16 17:45:12 GMT 2023 , Edited by admin on Sat Dec 16 17:45:12 GMT 2023
PRIMARY
RXCUI
6883
Created by admin on Sat Dec 16 17:45:12 GMT 2023 , Edited by admin on Sat Dec 16 17:45:12 GMT 2023
PRIMARY RxNorm
PUBCHEM
8226
Created by admin on Sat Dec 16 17:45:12 GMT 2023 , Edited by admin on Sat Dec 16 17:45:12 GMT 2023
PRIMARY
SMS_ID
100000080906
Created by admin on Sat Dec 16 17:45:12 GMT 2023 , Edited by admin on Sat Dec 16 17:45:12 GMT 2023
PRIMARY
DRUG CENTRAL
1764
Created by admin on Sat Dec 16 17:45:12 GMT 2023 , Edited by admin on Sat Dec 16 17:45:12 GMT 2023
PRIMARY
DRUG BANK
DB00353
Created by admin on Sat Dec 16 17:45:12 GMT 2023 , Edited by admin on Sat Dec 16 17:45:12 GMT 2023
PRIMARY
CAS
113-42-8
Created by admin on Sat Dec 16 17:45:12 GMT 2023 , Edited by admin on Sat Dec 16 17:45:12 GMT 2023
PRIMARY
HSDB
3364
Created by admin on Sat Dec 16 17:45:12 GMT 2023 , Edited by admin on Sat Dec 16 17:45:12 GMT 2023
PRIMARY
LACTMED
Methylergonovine
Created by admin on Sat Dec 16 17:45:12 GMT 2023 , Edited by admin on Sat Dec 16 17:45:12 GMT 2023
PRIMARY
ChEMBL
CHEMBL1201356
Created by admin on Sat Dec 16 17:45:12 GMT 2023 , Edited by admin on Sat Dec 16 17:45:12 GMT 2023
PRIMARY
IUPHAR
150
Created by admin on Sat Dec 16 17:45:12 GMT 2023 , Edited by admin on Sat Dec 16 17:45:12 GMT 2023
PRIMARY
FDA UNII
W53L6FE61V
Created by admin on Sat Dec 16 17:45:12 GMT 2023 , Edited by admin on Sat Dec 16 17:45:12 GMT 2023
PRIMARY
MESH
D008755
Created by admin on Sat Dec 16 17:45:12 GMT 2023 , Edited by admin on Sat Dec 16 17:45:12 GMT 2023
PRIMARY
ECHA (EC/EINECS)
204-027-0
Created by admin on Sat Dec 16 17:45:12 GMT 2023 , Edited by admin on Sat Dec 16 17:45:12 GMT 2023
PRIMARY
WIKIPEDIA
METHYLERGOMETRINE
Created by admin on Sat Dec 16 17:45:12 GMT 2023 , Edited by admin on Sat Dec 16 17:45:12 GMT 2023
PRIMARY
Related Record Type Details
SALT/SOLVATE -> PARENT
SALT/SOLVATE -> PARENT
Related Record Type Details
PARENT -> METABOLITE ACTIVE
Related Record Type Details
PARENT -> IMPURITY
Related Record Type Details
ACTIVE MOIETY